Clinical trial
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
NCT00382694 · Nordic Myeloma Study Group, Other · Unknown status
Key facts
| NCT number | NCT00382694 |
|---|---|
| Title | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients |
| Official title | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03 |
| Lead sponsor | Nordic Myeloma Study Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Fludarabine |
| Enrollment | 80 |
| Start date | May 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Sep 29, 2006 |
| Last update posted | Sep 29, 2006 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: